GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Anika Therapeutics Inc (NAS:ANIK) » Definitions » Cyclically Adjusted PB Ratio

Anika Therapeutics (Anika Therapeutics) Cyclically Adjusted PB Ratio : 1.30 (As of Apr. 30, 2024)


View and export this data going back to 1993. Start your Free Trial

What is Anika Therapeutics Cyclically Adjusted PB Ratio?

As of today (2024-04-30), Anika Therapeutics's current share price is $25.97. Anika Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was $19.96. Anika Therapeutics's Cyclically Adjusted PB Ratio for today is 1.30.

The historical rank and industry rank for Anika Therapeutics's Cyclically Adjusted PB Ratio or its related term are showing as below:

ANIK' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.88   Med: 3.76   Max: 7.84
Current: 1.3

During the past years, Anika Therapeutics's highest Cyclically Adjusted PB Ratio was 7.84. The lowest was 0.88. And the median was 3.76.

ANIK's Cyclically Adjusted PB Ratio is ranked better than
67.54% of 456 companies
in the Medical Devices & Instruments industry
Industry Median: 2.1 vs ANIK: 1.30

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Anika Therapeutics's adjusted book value per share data for the three months ended in Dec. 2023 was $14.479. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $19.96 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Anika Therapeutics Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Anika Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anika Therapeutics Cyclically Adjusted PB Ratio Chart

Anika Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.00 3.14 2.15 1.58 1.14

Anika Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.58 1.49 1.32 0.93 1.14

Competitive Comparison of Anika Therapeutics's Cyclically Adjusted PB Ratio

For the Medical Instruments & Supplies subindustry, Anika Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anika Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Anika Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Anika Therapeutics's Cyclically Adjusted PB Ratio falls into.



Anika Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Anika Therapeutics's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=25.97/19.96
=1.30

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anika Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Anika Therapeutics's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book=Book Value per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=14.479/129.4194*129.4194
=14.479

Current CPI (Dec. 2023) = 129.4194.

Anika Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201403 10.709 99.695 13.902
201406 10.974 100.560 14.123
201409 11.466 100.428 14.776
201412 11.992 99.070 15.666
201503 12.119 99.621 15.744
201506 12.701 100.684 16.326
201509 13.307 100.392 17.155
201512 14.022 99.792 18.185
201603 13.229 100.470 17.041
201606 13.833 101.688 17.605
201609 14.672 101.861 18.641
201612 15.230 101.863 19.350
201703 15.696 102.862 19.748
201706 16.656 103.349 20.858
201709 17.275 104.136 21.469
201712 17.939 104.011 22.321
201803 17.889 105.290 21.989
201806 16.909 106.317 20.583
201809 17.962 106.507 21.826
201812 18.551 105.998 22.650
201903 18.930 107.251 22.843
201906 18.204 108.070 21.800
201909 19.741 108.329 23.584
201912 20.155 108.420 24.059
202003 20.686 108.902 24.583
202006 20.307 108.767 24.163
202009 20.020 109.815 23.594
202012 19.010 109.897 22.387
202103 19.258 111.754 22.302
202106 19.892 114.631 22.458
202109 20.093 115.734 22.469
202112 19.880 117.630 21.873
202203 19.685 121.301 21.002
202206 19.602 125.017 20.292
202209 19.507 125.227 20.160
202212 19.526 125.222 20.181
202303 18.831 127.348 19.137
202306 18.695 128.729 18.795
202309 18.480 129.860 18.417
202312 14.479 129.419 14.479

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Anika Therapeutics  (NAS:ANIK) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Anika Therapeutics Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Anika Therapeutics's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Anika Therapeutics (Anika Therapeutics) Business Description

Traded in Other Exchanges
Address
32 Wiggins Avenue, Bedford, MA, USA, 01730
Anika Therapeutics Inc is an orthopedic medicines company. It is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies. The company focuses on orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies. Geographically, it derives a majority of its revenue from the United States.
Executives
Anne Nunes officer: SVP, Chief Operations Officer 32 WIGGINS AVENUE, BEDFORD MA 01730
Gary P Fischetti director 600 TECHNOLOGY PARK DRIVE, 4TH FLOOR, BILLERICA MA 01821
David Colleran officer: EVP, General Counsel, Corp Sec 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Cheryl R Blanchard director C/O ZIMMER, INC., P.O. BOX 708, WARSAW IN 46580
Michael L Levitz officer: EVP, CFO, Treasurer C/O ANALOGIC CORPORATION, 8 CENTENNIAL DRIVE, PEABODY MA 01960
Sheryl L Conley director C/O NEURONETICS, INC., 3222 PHOENIXVILLE PIKE, MALVERN PA 19355
Henneman John B Iii director 311 C ENTERPRISE DRIVE, PLAINSBORO NJ 08536
Raymond J Land director
Stephen Richard director C/O ANIKA THERAPEUTICS, INC., 32 WIGGINS AVENUE, BEDFORD MA 01730
James Loerop officer: EVP Business Development C/O ACLARIS THERAPEUTICS, INC., 640 LEE ROAD, SUITE 200, WAYNE PA 19087
Sylvia Cheung officer: CFO ANIKA THERAPEUTICS, INC., 32 WIGGINS AVENUE, BEDFORD MA 01730
Glenn R. Larsen director 32 WIGGINS AVENUE, BEDFORD MA 01730
Joseph I Bower director 32 WIGGINS AVENUE, BEDFORD MA 01730
Jeffery S Thompson director 1140 HAVENBROOK COURT, SUWANEE GA 30024
Joseph G Darling officer: President 501 MANDALAY AVE., UNIT 409, CLEARWATER BEACH FL 33767